Capricor Therapeutics (CAPR) Common Equity (2010 - 2026)

Capricor Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $278.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 118.34% year-over-year to $278.7 million; the TTM figure through Mar 2026 stood at $278.7 million (up 118.34% YoY), while the FY2025 annual figure was $305.8 million, up 110.22% from the prior year.
• Common Equity was $278.7 million for Q1 2026 at Capricor Therapeutics, down from $305.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $305.8 million in Q4 2025 to a low of -$1.8 million in Q3 2023.
• Historically, Common Equity has averaged $73.2 million across 5 years, with a median of $22.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 111.59% in 2023, then surged 3918.69% in 2024.
• A 5-year view of Common Equity shows it stood at $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then surged by 543.6% to $145.5 million in 2024, then soared by 110.22% to $305.8 million in 2025, then declined by 8.86% to $278.7 million in 2026.
• The last three Common Equity figures came in at $278.7 million (Q1 2026), $305.8 million (Q4 2025), and $83.9 million (Q3 2025), per Business Quant data.